Andexanet alfa for reversal of rivaroxaban in a child with intracranial hemorrhage

被引：3
|
作者：
Takasaki, Kaoru [1 ]
Hehir, David [2 ,3 ,4 ,5 ]
Raffini, Leslie [6 ,7 ]
Samelson-Jones, Benjamin J. [6 ,7 ,8 ]
Shih, Evelyn [1 ,9 ,10 ,11 ]
Dain, Aleksandra Sarah [1 ]
机构：
[1] Childrens Hosp Philadelphia, Div Hematol & Oncol, 3615 Civic Ctr Blvd,Room 314E, Philadelphia, PA 19104 USA
[2] Childrens Hosp Philadelphia, Div Cardiol, Philadelphia, PA USA
[3] Childrens Hosp Philadelphia, Div Cardiac Crit Care, Philadelphia, PA USA
[4] Univ Penn, Perelman Sch Med, Dept Anesthesia, Philadelphia, PA USA
[5] Univ Penn, Perelman Sch Med, Dept Crit Care, Philadelphia, PA USA
[6] Childrens Hosp Philadelphia, Div Hematol, Philadelphia, PA USA
[7] Univ Penn, Perelman Sch Med, Philadelphia, PA USA
[8] Raymond G Perelman Ctr Cellular & Mol Therapeut, Philadelphia, PA USA
[9] Childrens Hosp Philadelphia, Div Neurol, Philadelphia, PA USA
[10] Univ Penn, Dept Neurol, Philadelphia, PA USA
[11] Univ Penn, Dept Pediat, Philadelphia, PA USA
来源：
PEDIATRIC BLOOD & CANCER | 2022年 / 69卷 / 06期
基金：
美国国家卫生研究院;
关键词：
VENOUS THROMBOSIS;
D O I：
10.1002/pbc.29484
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages
    Barra, Megan E.
    Das, Alvin S.
    Hayes, Bryan D.
    Rosenthal, Eric S.
    Rosovsky, Rachel P.
    Fuh, Lanting
    Patel, Aman B.
    Goldstein, Joshua N.
    Roberts, Russel J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (07) : 1637 - 1647
  • [42] An Evaluation of Andexanet Alfa v. Standard of Care for Reversal of Doac-Induced Intracranial Hemorrhage-a Systematic Review and Meta-Analysis
    Xiang, Alexander J.
    Sadafi, Sarah
    Principato, Rachael
    Shaikh, Asim
    Nowrouzi, Mehrad
    Li, Allen
    Eshaghpour, Ali
    Crowther, Mark A.
    BLOOD, 2024, 144 : 5089 - 5090
  • [43] Andexanet Alfa, an Antidote for Uncontrollable Bleeding After Treatment With Rivaroxaban or Apixaban
    Goldstein, Joshua N.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (09) : 7 - 15
  • [44] Concomitant andexanet alfa and 4 F-PCC for Factor Xa inhibitor associated intracranial hemorrhage
    Orban III, James E.
    Ruckel, Cassidy
    Harlan, Sarah
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2023, 233
  • [45] Andexanet alfa for reversal of direct factor Xa inhibitor anticoagulation
    不详
    AUSTRALIAN PRESCRIBER, 2024, 47 (01) : 31 - 32
  • [46] Andexanet alfa: A Novel Factor Xa Inhibitor Reversal Agent
    Powell, Jason
    Taylor, James
    Garland, Scott G.
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (09) : 940 - 946
  • [47] Andexanet Alfa Versus Prothrombin Complex Concentrates/Blood Products as Apixaban/Rivaroxaban Reversal Agents: A Survey Among Pediatric Hematologists
    Rodriguez, Vilmarie
    Stanek, Joseph
    Kerlin, Bryce A.
    Dunn, Amy L.
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2022, 28
  • [48] Andexanet Alfa Versus Prothrombin Complex Concentrates/Blood Products as Apixaban/Rivaroxaban Reversal Agents: A Survey Among Pediatric Hematologists
    Rodriguez, Vilmarie
    Stanek, Joseph
    Kerlin, Bryce A.
    Dunn, Amy L.
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2022, 28
  • [49] Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation
    Ghadimi, Kamrouz
    Dombrowski, Keith E.
    Levy, Jerrold H.
    Welsby, Ian J.
    EXPERT REVIEW OF HEMATOLOGY, 2016, 9 (02) : 115 - 122
  • [50] Andexanet Alfa, the Possible Alternative to Protamine for Reversal of Unfractionated Heparin
    Maneno, John N.
    Ness, Genevieve Lynn
    ANNALS OF PHARMACOTHERAPY, 2021, 55 (02) : 261 - 264
12345